Novel Bruton's Tyrosine Kinase Inhibitor Bgb-3111 Demonstrates Potent Activity in Mantle Cell Lymphoma

被引：3
|
作者：
Li, Carrie J.
Liu, Yang
Bell, Taylor
Wang, Jack
Guo, Hui
Ahmed, Makhdum
Zhang, Hui
Lam, Laura T.
Nomie, Krystle
Wang, Lai
Zhang, Liang
Wang, Michael
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5374.5374
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5374
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
    Li, Carrie J.
    Jiang, Changying
    Liu, Yang
    Bell, Taylor
    Ye, Yin
    Huang, Shengjian
    Guo, Hui
    Zhang, Hui
    Wang, Lai
    Wang, Jing
    Nomie, Krystle
    Zhang, Liang
    Wang, Michael
    Ma, Wencai
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 267 - 277
  • [2] Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma
    Tam, Constantine S.
    Wang, Michael
    Simpson, David
    Opat, Stephen
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won-Seog
    Hilger, James
    Huang, Jane
    Novotny, William
    Trotman, Judith
    BLOOD, 2018, 132
  • [3] Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
    Guo, Yunhang
    Liu, Ye
    Hu, Nan
    Yu, Desheng
    Zhou, Changyou
    Shi, Gongyin
    Zhang, Bo
    Wei, Min
    Liu, Junhua
    Luo, Lusong
    Tang, Zhiyu
    Song, Huipeng
    Guo, Yin
    Liu, Xuesong
    Su, Dan
    Zhang, Shuo
    Song, Xiaomin
    Zhou, Xing
    Hong, Yuan
    Chen, Shuaishuai
    Cheng, Zhenzhen
    Young, Steve
    Wei, Qiang
    Wang, Haisheng
    Wang, Qiuwen
    Lv, Lei
    Wang, Fan
    Xu, Haipeng
    Sun, Hanzi
    Xing, Haimei
    Li, Na
    Zhang, Wei
    Wang, Zhongbo
    Liu, Guodong
    Sun, Zhijian
    Zhou, Dongping
    Li, Wei
    Liu, Libin
    Wang, Lai
    Wang, Zhiwei
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 7923 - 7940
  • [4] BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
    Li, Na
    Sun, Zhijian
    Liu, Ye
    Guo, Mingming
    Zhang, Yilu
    Zhou, Dongping
    Zhang, Bo
    Su, Dan
    Zhang, Shuo
    Han, Jing
    Gao, Yajuan
    Guo, Yunhang
    Wang, Zhiwei
    Wei, Min
    Luo, Lusong
    Wang, Lai
    CANCER RESEARCH, 2015, 75
  • [5] Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
    Wang, Xianhuo
    Fei, Yue
    Liu, Xia
    Zhang, Tingting
    Li, Wei
    Jia, Xiaohui
    Liu, Xianming
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Ren, Xiubao
    Zhai, Qiongli
    Meng, Bin
    Li, Lanfang
    Zhang, Huilai
    AGING-US, 2021, 13 (17): : 21102 - 21121
  • [6] Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Zhou, Daobin
    Guo, Haiyi
    Wang, Aihua
    Hilger, James
    Huang, Jane
    Novotny, William
    Osman, Muhtar
    Zhu, Jun
    BLOOD, 2018, 132
  • [7] The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents
    Tarantelli, Chiara
    Zhang, Lu
    Curti, Elisabetta
    Gaudio, Eugenio
    Spriano, Filippo
    Priebe, Valdemar
    Cascione, Luciano
    Arribas, Alberto J.
    Zucca, Emanuele
    Rossi, Davide
    Stathis, Anastasios
    Bertoni, Francesco
    HAEMATOLOGICA, 2019, 104 (07) : e307 - e309
  • [8] Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies
    Ou, Ying
    Wang, Kun
    Liu, Lucy
    Jindal, Ashutosh
    Gao, Yuying
    Sahasranaman, Sri
    BLOOD, 2019, 134
  • [9] A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia
    An, Gang
    Zhou, Daobin
    Cheng, Shu
    Zhou, Keshu
    Li, Jianyong
    Zhou, Jianfeng
    Xie, Liping
    Jin, Jie
    Zhong, Liye
    Yan, Lingzhi
    Guo, Haiyi
    Du, Chenmu
    Zhong, Jinhua
    Yu, Yiling
    Wu, Binghao
    Qiu, Lugui
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5492 - 5501
  • [10] BTK inhibitor BGB-3111 demonstrates anti-tumor activity in solid tumor models
    Hu, Nan
    Zhang, Jiye
    He, Min
    Zhang, Shuo
    Liu, Yong
    Wang, Lai
    CANCER RESEARCH, 2017, 77
12345